Table 1.
Table 1A. Use of Antioxidants in FA patients
Table 1B. Logistic regression analysis of clinical variables and antioxidant use
| Agent | % taking | Median dose | Interquartile Range | Median Dose/weight | Interquartile Range | Median Duration (years) |
|---|---|---|---|---|---|---|
| Vitamin E | 53 | 800 IU | 700–1200 | 11.3 IU/kg | 8.2–20 IU/kg | >1 |
| Coenzyme Q10 | 43 | 300 mg | 200–400 | 3.9 mg/kg | 2.2–7.7 mg/kg | >1 |
| Idebenone | 17 | 390 mg | 225–450 | 6.8 mg/kg | 4.4–10 mg/kg | >1 |
| NAC | 9 | 1100 mg | 550–2250 | 29.5 mg/kg | 15.8–52.4 mg/kg | >1 |
| Selenium | 7 | 200 mg | 100–200 | 2.7 mg/kg | 0.98–4.7 mg/kg | >1 |
| Agent | Age | Gender | GAA Repeat Length | Presence of Cardiomyopathy | FARS score | |
| Vitamin E | 0.56 | 0.37 | 0.59 | 0.32 | 0.032 | |
| CoQ | 0.73 | 0.69 | 0.35 | 0.50 | 0.13 | |
| Idebenone | 0.0005* | 0.32 | 0.005* | 0.029 | 0.13 | |
| NAC | 0.24 | 0.41 | 0.073 | 0.97 | 0.54 | |
| Selenium | 0.32 | 0.54 | 0.14 | 0.62 | 0.025 | |
*
=statistically significant. In panel A, the use of different antioxidants is displayed. In panel B, Logistic regression was used to define the patient characteristics associated with a greater likelihood for use of each antioxidant (p values shown in table).